Medical Technology Innovations: Better patient outcomes for less money, startups are taking this $3.3 trillion industry seriously.

AliveCor's
Reading Time: 4 minutes

Last year, the Apple Watch began its transformation from a consumer product to a healthcare tech one. In November, the FDA announced the approval of the first medical Apple Watch accessory, AliveCor’s KardiaBand. The novel health-related technologies leverage the Apple Watch’s heart rate monitoring technology and combine it with an additional sensor to provide EKG readings in under a minute. According to their press release, this data gives consumers much-needed information about their heart health and the ability to forward that data to their doctors for further analysis.

The KardiaBand is just one example of a drive to use health-related technologies to disrupt an industry that has yet to fully capitalize on the digital revolution. As healthcare costs continue to skyrocket, the industry needs more efficient, efficacious, and affordable ways and innovative ideas in healthcare to provide high-quality, error-free care.

Health Related Technologies:

According to the US government, in 2016, Americans spent $3.3 trillion on healthcare, about 18% of GDP. Though the US is notorious for its high healthcare costs, other developed countries are experiencing rising costs as well. The last decade has seen Japan’s healthcare costs increase by about ¥10 trillion ($94.3 billion). Zeke Emanuel, an oncologist and medical ethicist who worked on the Affordable Care Act, cites many reasons for rising medical costs. Among them is wasteful spending on unnecessary tests and services, which he estimates costs $200 billion a year. Eliminating a fraction of this sum is a huge opportunity for entrepreneurs in this space.

The Medical Technology Opportunity

As consumers become more accustomed to internet-enabled devices such as smart watches, IoT appliances, and in-home assistants like Amazon’s Alexa, it won’t be long before they start to expect similar health-related technologies/healthcare tech from the healthcare industry. Current innovative ideas in healthcare include telemedicine (Skyping your doctor), mobile apps, and leveraging artificial intelligence to streamline diagnostics. But those innovations in healthcare technology are just the beginning of the future of education technology.

As is common in such digital transformations, the healthcare tech space is crowded with both new medical technology innovators and established firms. In the case of the latter, a reduction in overall healthcare spending will have a big impact on their bottom line. Up and down the value chain, there are almost endless opportunities for greater efficiency.

One example: as medicine becomes increasingly data-driven, fewer tests and less prescription experimentation will be required to accurately diagnose and treat illness. Another example: as diagnostic equipment becomes more compact, hospitals will start to lose their monopoly on a panoply of services.

Healthcare’s Artificial Intelligence Revolution

Most data scientists define artificial intelligence as the ability of algorithms to process vast sets of data, recognize patterns within that data and make decisions based on those discoveries. Specifically, we’ve been seeing lots of artificial intelligence applications come from the diagnostic side of healthcare.

Last year, a Radiology study found that artificial intelligence could diagnose tuberculosis. First, a deep neural network (DNN) was “trained” by showing it a series of TB-positive and TB-negative x-rays, then the system was shown a new series of x-rays and asked to make a diagnosis. Overall, the system correctly identified TB-positive and negative X-rays 96% of the time. Just last month, DeepMind, a Google subsidiary, reported similarly fascinating results when it announced it could leverage AI to detect certain eye diseases. The London-based company will soon partner with the UK’s National Institute of Health to conduct further trials to validate its findings.

For us, the DeepMind and NIH partnership (not to mention all the additional studies that will come from their collaboration) encapsulates at least one of the challenges that come with innovating in this industry: each discovery has regulatory hurdles to overcome before it becomes available in the marketplace.

Investing in Medical Technology

As innovations in medical technology and data science become increasingly integrated within this industry, investors can’t help but see the potential in health-related technologies. According to a Silicon Valley Bank report, US healthcare venture fundraising set a record last year, reaching $9.1 billion — a 26% increase over 2016. International markets are seeing investment as well. Last year, Ping An Good Doctor, a Chinese medical-services app, raised $500m.

graph
2017 was a record year for VC funding in biotech, genetics. Source: PitchBook

Amid the rising tide of excitement and opportunity in this rapidly changing industry, the biggest winners from a potential healthcare tech transformation will be the patients who receive better care and those who will avoid becoming patients at all.

.    .    .

Disclaimer: Articles or information from third-party sources outside of this domain may discuss Propel(x) or relate to information contained herein, but Propel(x) does not approve and is not responsible for such content. Hyperlinks to third-party sites, or reproduction of third-party content, do not constitute an approval or endorsement by Propel(x) or Hubble Investments, Propel(x)’ broker-dealer affiliate, of the linked or reproduced content.

Private Placements are a high-risk investment. An investment in such offerings is speculative and an investor could experience an entire loss of principal. Past performance may not be indicative of future results. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio.

Information provided in this article is not intended to be nor should it be construed or used as, investment, tax, or legal advice, a recommendation, or an offer to sell, or a solicitation of an offer to buy, an interest, directly or indirectly, in any company.

Twitter
LinkedIn
Facebook

Discover more from Propel(x) Insider

Sign up now and learn about Startups, Hedge Funds, SPVs and more

Start Investing Today​